JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
|
Citation:
|
JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
|
JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
|
Citation:
|
JIANG Su-jing, XIE Cong-ying, LU Hong-lian. Overall Survival with Durvalumab after Chemoradio-therapy in Stage Ⅲ NSCLC[J]. Journal of Evidence-Based Medicine, 2020, 20(1): 49-52. DOI: 10.12019/j.issn.1671-5144.2020.01.011
|
DownLoad: